Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
THR-184
print preview
bookmark
share with colleague
General Information
Company
Thrasos Therapeutics Inc.
Description
Small peptide that selectively activates ALK2 and ALK3
Molecular Target
Activin receptor-like kinase 2 (ALK2) (ACVR1)
;
Activin receptor-like kinase 3 (ALK3)
Mechanism of Action
Latest Stage of Development
Phase I
Indication
Renal damage
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy